A Study of ZT002 Injection With Subjects With Overweight or Obesity

• ZT002 Injection (Drug): Administered SC
• ZT002 Placebo (Drug): Administered SC

Primary outcomes

• The percentage change from baseline in weight after 24 weeks of treatment. [baseline, 24 weeks]

Secondary outcomes

• The proportion of subjects with weight loss of ≥ 5%, ≥ 10%, and ≥ 15% from baseline after 24 weeks of treatment; [24 weeks]

Sex: All, ages: 18 Years to 75 Years

Inclusion Criteria:

* Age ≥ 18 years and ≤ 75 years.
* BMI ≥28 kg/m², or 24 kg/m2 ≤ BMI < 28 kg/m2 with at least one comorbidity (pre-diabetes, hypertension, hyperlipidemia, fatty liver, obstructive sleep apnoea syndrome due to overweight, weight-bearing joint pain, etc.)
* Weight change is not more than 5% with diet and exercise control alone within 3 months prior to screening.

Exclusion Criteria:

* Previous diagnosis of diabetes; or HbA1c ≥ 6. 5% or fasting blood glucose ≥ 7.0 mmol/L at screening.
* Have used medicines or treatments that affect weight within 3 months prior to screening.
* History of acute or chronic pancreatitis.
* Personal or family (parents, children, and siblings) history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type II (MEN2).
* History of definite mental disease within 2 years prior to screening or prior suicidal tendency or suicidal behavir; or PHQ-9 scale score is ≥ 15 at screening; or C-SSRS questionnaire is either class 4 or 5 at screening.

• Linong Ji, MD, Principal investigator, Peking University People's Hospital